|
|
Testis Cancer / Treatments
Treatment Overview
Treatment for GCT depends on tumor type and the extent of tumor growth. In general, there are three stages of tumor progression related to the anatomical sites in which cancer is found (table 2). Stage I cancer is limited to the testicle with no evidence of lymph node involvement. Stage II disease signifies the presence of lymph node involvement at predictable sites known for tumor spread within the abdomen or pelvis (retroperitoneum) and can be evaluated with CT scan. With Stage III, the cancer has spread to areas outside of these usual sites and may involve the lungs, distant lymph nodes, or other organs. Patients with Stage III cancer may have very high tumor marker concentrations on blood tests without evidence of tumor spread seen.
| Stage |
Tumor |
Lymph Nodes |
Metastases |
Markers |
| 0 |
Intratubular germ cell neoplasia (cis) |
0 |
0 |
normal |
| IA |
Limited to tesits, no vascular invasion |
0 |
0 |
normal |
| IB |
Localle invasive into vascular and/or lymphatic structures, cord, scrotal skin, or tunica albuginea |
0 |
0 |
normal |
| IS |
Any degree of local tumor growth |
0 |
0 |
Elevated |
| IIA |
Any degree of local tumor growth |
<2 cm |
0 |
Normal or mildly elevated |
| IIB |
Any degree of local tumor growth |
>2 cm, <5 cm |
0 |
Normal or mildly elevated |
| IIC |
Any degree of local tumor growth |
<5 cm |
0 |
Normal or mildly elevated |
| IIIA |
Any degree of local tumor growth |
Any size |
Non-regional nodes or pulmonary |
Normal or mildly elevated |
| IIIB |
Any degree of local tumor growth |
Any size |
None, non-regional nodes or pulmonary |
LDH 1.5-10xNl
HCG 5-50x103
AFP 1-10x103
|
| IIIC |
Any degree of local tumor growth |
Any size |
None, non-regional nodes, pulmonary or visceral |
LDH >10xNl
HCG > 50x103
AFP > 10x103
|
[ݦlt;A HREF="#top" onMouseOver="self.status='zip back to top'; return true">back to topݝ
As mentioned, seminomatous tumors are extremely sensitive to radiation and chemotherapy with excellent response rates seen after treatment. Stage I seminoma is treated with orchidectomy followed by radiation therapy to areas where tumor spread would be expected (the retroperitoneum). Cure rates with this treatment have been reported as high as 98%. Without radiation therapy, a relapse rate of 15% can be expected. Stage II, low volume disease, is also treated with radiation therapy with slight modification of the treatment method, again with excellent results of 85-95% cure. Stage III, high volume disease requires chemotherapy treatment following orchidectomy and also has good response with 70-80% cure rates (see figure 2 at end of document).
Nonseminomatous tumors do not exhibit good response to radiation treatment and must be managed with chemotherapy and further surgery. Approximately one-third of all patients initially diagnosed with Stage I, non-seminoma will actually have retroperitoneal lymph nodes that contain tumor (Stage II). Surgery is indicated for removal of lymph nodes in the retroperitoneum that are likely to contain cancer cells for both staging and curative treatment. Some sub-stages of disease and cell type can be managed without chemotherapy or surgery but strict long-term surveillance with routine CT scans and chest x-rays is absolutely required (see figure 3 at end of document). Testis cancer spreads predictably along pathways of lymphatic drainage. Left-sided cancers will commonly go to the lymph nodes on the left side of the aorta (para-aortic and preaortic), up to the level of the vein from the left kidney (left renal vein), and rarely cross over to the right side (see figure 1). On the other hand, right-sided tumors often cross over to the left side. Landing areas for right-sided tumors include the right side of the inferior vena cava (precaval) and the area between the aorta and vena cava (interaortal caval).
|
Website Disclaimer
© 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008 Content by Cornell University. All rights reserved.
© 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008 Design and architecture, Healthcommunities.com. All rights reserved.

|
|